Truqap is a kinase inhibitor that works by blocking pathways that enable the most cancers cells endure and mature, so lessens cancer development. Truqap is from a class of medicines referred to as an AKT inhibitor. Truqap received FDA approval on November 17, 2023, following constructive outcomes in the CAPItello-291 https://rituximab68912.snack-blog.com/34759742/the-basic-principles-of-inavolisib